{
    "title": "107_s754",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Drug Competition Act of 2002''.\n\nSEC. 2. FINDINGS.\n\n    Congress finds that--\n            (1) prescription drug prices are increasing at an alarming \n        rate and are a major worry of many senior citizens and American \n        families;\n            (2) there is a potential for companies with patent rights \n        regarding brand name drugs and companies which could \n        manufacture generic versions of such drugs to enter into \n        financial deals that could tend to restrain trade and greatly \n        reduce competition and increase prescription drug expenditures \n        for American citizens; and\n            (3) enhancing competition among these companies can \n        significantly reduce prescription drug expenditures for \n        Americans.\n\nSEC. 3. PURPOSES.\n\n    The purposes of this Act are--\n            (1) to provide timely notice to the Department of Justice \n        and the Federal Trade Commission regarding agreements between \n        companies with patent rights regarding brand name drugs and \n        companies which could manufacture generic versions of such \n        drugs; and\n            (2) by providing timely notice, to enhance the \n        effectiveness and efficiency of the enforcement of the \n        antitrust and competition laws of the United States.\n\nSEC. 4. DEFINITIONS.\n\n    In this Act:\n            (1) ANDA.--The term ``ANDA'' means an Abbreviated New Drug \n        Application, as defined under section 201(aa) of the Federal \n        Food, Drug, and Cosmetic Act (21 U.S.C. 321(aa)).\n            (2) Assistant attorney general.--The term ``Assistant \n        Attorney General'' means the Assistant Attorney General in \n        charge of the Antitrust Division of the Department of Justice.\n            (3) Brand name drug.--The term ``brand name drug'' means a \n        drug approved under section 505(c) of the Federal Food, Drug, \n        and Cosmetic Act (21 U.S.C. 355(c)).\n            (4) Brand name drug company.--The term ``brand name drug \n        company'' means the party that received Food and Drug \n        Administration approval to market a brand name drug pursuant to \n        an NDA, where that drug is the subject of an ANDA, or a party \n        owning or controlling enforcement of any patent listed in the \n        Approved Drug Products With Therapeutic Equivalence Evaluations \n        of the Food and Drug Administration for that drug, under \n        section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 \n        U.S.C. 355(b)).\n            (5) Commission.--The term ``Commission'' means the Federal \n        Trade Commission.\n            (6) Generic drug.--The term ``generic drug'' means a \n        product that the Food and Drug Administration has approved \n        under section 505(j) of the Federal Food, Drug, and Cosmetic \n        Act (21 U.S.C. 355(j)).\n            (7) Generic drug applicant.--The term ``generic drug \n        applicant'' means a person who has filed or received approval \n        for an ANDA under section 505(j) of the Federal Food, Drug, and \n        Cosmetic Act (21 U.S.C. 355(j)).\n            (8) NDA.--The term ``NDA'' means a New Drug Application, as \n        defined under section 505(b) et seq. of the Federal Food, Drug, \n        and Cosmetic Act (21 U.S.C. 355(b) et seq.)\n\nSEC. 5. NOTIFICATION OF AGREEMENTS.\n\n    (a) In General.--\n            (1) Requirement.--A generic drug applicant that has \n        submitted an ANDA containing a certification under section \n        505(j)(2)(vii)(IV) of the Federal Food, Drug, and Cosmetic Act \n        (21 U.S.C. 355(j)(2)(vii)(IV)) and a brand name drug company \n        that enter into an agreement described in paragraph (2), prior \n        to the generic drug that is the subject of the application \n        entering the market, shall each file the agreement as required \n        by subsection (b).\n            (2) Definition.--An agreement described in this paragraph \n        is an agreement regarding--\n                    (A) the manufacture, marketing or sale of the brand \n                name drug that is the subject of the generic drug \n                applicant's ANDA;\n                    (B) the manufacture, marketing or sale of the \n                generic drug that is the subject of the generic drug \n                applicant's ANDA; or\n                    (C) the 180-day period referred to in section \n                505(j)(5)(B)(iv) of the Federal Food, Drug, and \n                Cosmetic Act (21 U.S.C. 355(j)(5)(B)(iv)) as it applies \n                to such ANDA or to any other ANDA based on the same \n                brand name drug.\n    (b) Filing.--\n            (1) Agreement.--The generic drug applicant and the brand \n        name drug company entering into an agreement described in \n        subsection (a)(2) shall file with the Assistant Attorney \n        General and the Commission the text of any such agreement, \n        except that the generic drug applicant and the brand-name drug \n        company shall not be required to file an agreement that solely \n        concerns--\n                    (A) purchase orders for raw material supplies;\n                    (B) equipment and facility contracts;\n                    (C) employment or consulting contracts; or\n                    (D) packaging and labeling contracts.\n            (2) Other agreements.--The generic drug applicant and the \n        brand name drug company entering into an agreement described in \n        subsection (a)(2) shall file with the Assistant Attorney \n        General and the Commission the text of any other agreements not \n        described in subsection (a)(2) between the generic drug \n        applicant and the brand name drug company which are contingent \n        upon, provide a contingent condition for, or are otherwise \n        related to an agreement which must be filed under this Act.\n            (3) Description.--In the event that any agreement required \n        to be filed by paragraph (1) or (2) has not been reduced to \n        text, both the generic drug applicant and the brand name drug \n        company shall file written descriptions of the non-textual \n        agreement or agreements that must be filed sufficient to reveal \n        all of the terms of the agreement or agreements.\n\nSEC. 6. FILING DEADLINES.\n\n    Any filing required under section 5 shall be filed with the \nAssistant Attorney General and the Commission not later than 10 \nbusiness days after the date the agreements are executed.\n\nSEC. 7. DISCLOSURE EXEMPTION.\n\n    Any information or documentary material filed with the Assistant \nAttorney General or the Commission pursuant to this Act shall be exempt \nfrom disclosure under section 552 of title 5, and no such information \nor documentary material may be made public, except as may be relevant \nto any administrative or judicial action or proceeding. Nothing in this \nsection is intended to prevent disclosure to either body of Congress or \nto any duly authorized committee or subcommittee of the Congress.\n\nSEC. 8. ENFORCEMENT.\n\n    (a) Civil Penalty.--Any brand name drug company or generic drug \napplicant which fails to comply with any provision of this Act shall be \nliable for a civil penalty of not more than $11,000, for each day \nduring which such entity is in violation of this Act. Such penalty may \nbe recovered in a civil action brought by the United States, or brought \nby the Commission in accordance with the procedures established in \nsection 16(a)(1) of the Federal Trade Commission Act (15 U.S.C. 56(a)).\n    (b) Compliance and Equitable Relief.--If any brand name drug \ncompany or generic drug applicant fails to comply with any provision of \nthis Act, the United States district court may order compliance, and \nmay grant such other equitable relief as the court in its discretion \ndetermines necessary or appropriate, upon application of the Assistant \nAttorney General or the Commission.\n\nSEC. 9. RULEMAKING.\n\n    The Commission, with the concurrence of the Assistant Attorney \nGeneral and by rule in accordance with section 553 of title 5 United \nStates Code, consistent with the purposes of this Act--\n            (1) may define the terms used in this Act;\n            (2) may exempt classes of persons or agreements from the \n        requirements of this Act; and\n            (3) may prescribe such other rules as may be necessary and \n        appropriate to carry out the purposes of this Act.\n\nSEC. 10. SAVINGS CLAUSE.\n\n    Any action taken by the Assistant Attorney General or the \nCommission, or any failure of the Assistant Attorney General or the \nCommission to take action, under this Act shall not bar any proceeding \nor any action with respect to any agreement between a brand name drug \ncompany and a generic drug applicant at any time under any other \nprovision of law, nor shall any filing under this Act constitute or \ncreate a presumption of any violation of any antitrust or competition \nlaws.\n\nSEC. 11. EFFECTIVE DATE.\n\n    This Act shall--\n            (1) take effect 30 days after the date of enactment of this \n        Act; and\n            (2) shall apply to agreements described in section 5 that \n        are entered into 30 days after the date of enactment of this \n        Act.\n\n            Passed the Senate November 18, 2002.\n\n            Attest:\n\n                                                  JERI THOMSON,\n\n                                                             Secretary."
}